Merck con Keytruda No ha Conseguido el Objetivo Principal en el ensayo de Fase III para el Tratamiento de Primera línea en Small Cell Lung Cancer .

Merck's Keytruda shows mixed results in phase 3 trial for small cell lung cancer

(Reuters) - Merck & Co said a phase 3 trial of cancer drug Keytruda in combination with chemotherapy showed an increase in the amount of time patients lived with small cell lung cancer without it getting worse, but did not extend overall survival.

While the blockbuster drug showed improvement in overall survival for patients treated with Keytruda in combination with chemotherapy, it did not meet statistical significance, the company said on Monday. ...

**********************

Tratamientos para el Cancer de Pulmón Micricitico ( SMALL CELL LUNG CANCER ) para Primera, Segunda y Tercera línea actuales :